Alloreactivity compromising clinical outcomes in stem cell transplantation is observed despite HLA matching of donors and recipients. This has its origin in the variation between the exomes of the two, which provides the basis for minor histocompatibility antigens (mHA). The mHA presented on the HLA class I and II molecules and the ensuing T cell response to these antigens results in graft versus host disease. In this paper, results of a whole exome sequencing study are presented, with resulting alloreactive polymorphic peptides and their HLA class I and HLA class II (DRB1) Introduction.
Abstract.
Alloreactivity compromising clinical outcomes in stem cell transplantation is observed despite HLA matching of donors and recipients. This has its origin in the variation between the exomes of the two, which provides the basis for minor histocompatibility antigens (mHA). The mHA presented on the HLA class I and II molecules and the ensuing T cell response to these antigens results in graft versus host disease. In this paper, results of a whole exome sequencing study are presented, with resulting alloreactive polymorphic peptides and their HLA class I and HLA class II (DRB1) binding affinity quantified. Large libraries of potentially alloreactive recipient peptides binding both sets of molecules were identified, with HLA-DRB1 presenting an order of magnitude greater number of peptides. These results are used to develop a quantitative framework to understand the immunobiology of transplantation. A tensor-based approach is used to derive the equations needed to determine the alloreactive donor T cell response from the mHA-HLA binding affinity and protein expression data. This approach may be used in future studies to simulate the magnitude of expected donor T cell response and risk for alloreactive complications in HLA matched or mismatched hematopoietic cell and solid organ transplantation.
Introduction.
Graft-versus-host Disease (GVHD) represents a significant cause of morbidity and mortality in stem-cell transplant (SCT) recipients 1 . GVHD in an HLA-matched allogeneic stem cell transplant is the archetype of an adaptive immune response with donor derived T cells responding to recipient antigens presented on shared HLA class I and class II antigens 2, 3, 4 . Since the beginning, HLA matching has been the bedrock principle of donor selection in SCT, and this is particularly so when the donor is not a close relative 5, 6 . Improvements in the fidelity of HLA matching between unrelated transplant donors and recipients has yielded incremental benefits in patient outcomes, with improvements in survival resulting from both a reduction in GVHD risk as well as reduction in graft loss and optimization of relapse risk.
Nevertheless, GVHD remains a therapeutic challenge, and there is little that can be done to predict the outcomes of specific donor-recipient pairs.
This challenge may be surmounted by accounting for genomic variation between the donors and recipients which yields the peptides presented on HLA molecules, known as minor histocompatibility antigens (mHA) 7, 8 . While mHA have had a recognized pathophysiologic role in allogeneic SCT outcomes, especially in GVHD pathogenesis, it has not been possible to apply the notion to clinical practice because mHA characterization is a cumbersome process 9, 10, 11, 12 . Two developments in the past decade have changed this situation. One, the emergence of next generation DNA sequencing techniques, such as single nucleotide polymorphism mapping 13, 14 and whole exome sequencing (WES) to identify the potential antigenic differences 15, 16 . The second is the development of machine learning algorithms which allow determination of the binding affinity that different antigens may have for specific HLA molecules 17, 18, 19 . These two techniques have been combined to develop algorithms that may be used to determine the complex array of recipient antigens that a given donor T cells may encounter in a recipient 20, 21 . This knowledge of mHA in turn may allow simulation of alloreactive T cell responses in equivalently HLA matched SCT donor-recipient pairs (DRP) to identify donors with optimal alloreactivity.
Studies reporting exome-wide or other genomic disparities in donors and recipients, have demonstrated a large body of DNA sequence differences between transplant donors and recipients, independent of relatedness and HLA matching 14, 15, 16 . These large genomic differences have been translated to peptides and HLA affinities for the resulting peptides determined 20 . This too yields large libraries of antigens which may be analyzed by either simulating alloreactive T cell responses or by statistical methodology to determine predictive power for alloreactive T cell responses 22, 23 . To date, these models have examined recipient peptide presentation on HLA class I and studied the resulting associations.
As noted above, HLA-matched SCT remains fraught with uncertainty as patients with HLAmatched donors continue to have disparate outcomes 24, 25 . A quantitative model of transplant alloreactivity would allow a more complete understanding of the molecular immunology of SCT, help to identify the most suitable donors for specific recipients, and allow personalized determination of the optimal level of immunosuppression. A central assumption in one such quantitative model, the dynamical system model of T cell responses, is that alloreactivity (such as GVHD) risk is a function of the cumulative mHA variation in the context of the HLA type of each donor-recipient pair (DRP), and may thus be regarded as an alloreactivity potential for that pair 15, 20, 26 . Clinical outcomes partially depend on the cumulative donor T cell responses to the burden of polymorphic recipient peptides. Previous work applying this dynamical system model to HLA class I presented molecules demonstrates that there are large differences in the simulated T cell responses between different HLA matched DRP 22, 23 . Herein, 
Methods.
After obtaining approval from the institutional review board at the Virginia Commonwealth University, whole exome sequencing (WES) was performed on previously cryopreserved DNA samples from 77 HLAmatched DRP (Supplementary Table 1) as previously described 15, 22 . Briefly, whole exome sequences from each DRP were compared with each other, as well as to a standard reference exome. All nonsynonymous single-nucleotide polymorphisms (nsSNPs) present in the recipient and donor were identified and recorded in the .vcf format. Subsequent processing of the .vcf files was done using custom python scripts to remove synonymous mutations, eliminate duplicates, and record the coordinates of the SNPs. Non-synonymous SNPs that exist in the recipient but not in the donor were recorded and identified as potential source of alloreactive antigens. Non-synonymous, single nucleotide polymorphisms (nsSNP) in each DRP would correspond to potential antigens due to the resulting amino acid substitution in oligopeptides which bind HLA in that DRP ( Figure 1A ).
To derive the peptide sequences for this study, an average peptide length of 15 amino acids for HLA class II HLA was used 27 . HLA class I bound 9-mer peptides were generated as previously described 20 .
Each of the nsSNPs could potentially be incorporated into the alloreactive peptide of 15 amino acids.
The position of the nsSNP encoded polymorphic amino acid in the peptide could vary from the Nterminus to the C-terminus of the peptide. The possible library of peptides will thus be contained within a 29-mer oligopeptide ( Figure 1B) . Thus, there are 15 different HLA-II binding peptides that could potentially be generated from each nsSNP identified by WES. ANNOVAR was used to generate 29-mer peptides for each nsSNP respectively to study HLA class II presentation. In ANNOVAR, a sliding window method was used with the "seq_padding" option of the "annotate_variation" function to generate the 15 different 15-mers resulting from each nsSNP. Tissue expression of the proteins from which the peptides were derived was determined as previously described 23 .
Once the peptide library was created for each DRP, the HLA types for the recipient were tabulated from the medical records. For class II HLA, HLA-DRB1 alleles for each patient were recorded. Each patient's HLA-DRB1 allele types (and HLA class I alleles, as previously described) along with peptide library were analyzed using NetMHCIIpan 2.0 to derive the binding affinity of each peptide-HLA complex. This was given as an IC50 (half-maximal inhibitory concentration) for each peptide, measured in nano-Molar. This measure of binding affinity provided the concentration of peptide required to displace 50% of a standard peptide from the HLA type to which it would have been bound.
Peptides present in the recipient but absent in the donor, generated from the ANNOVAR sliding window
with IC50 values for all the different patient HLA types were tabulated and duplicates were deleted. Any peptide with the same amino acid sequence but different SNP position along the peptide must have generated from a different area of the exome and was therefore retained in the enumeration. When compiling the peptides binding to different HLA alleles, the patients with homozygous allele for DRB1
had their peptide values doubled to simulate having double the normal number of allele-specific HLA bound peptides presented. Analysis of the number of strongly bound (SB; IC50 £50 nM) and bound peptides (BP; IC50 £500 nM) for each patient-HLA allele combination was done by listing the peptides in descending order of binding affinity, as measured by IC50 levels (Table 1A & 1B) . HLA class I and HLA class II bound peptides were compared numerically for this perspective paper. (Table 1A) . This is likely an effect of the randomness observed in exome sequence variation, and the variation in HLA binding affinity of the resulting alloreactive peptides, and illustrates the potential for variability in alloreactive antigen presentation between different donors and recipients who undergo SCT.
Results

HLA class II bound alloreactive peptides
Comparing HLA class I and II bound alloreactive peptides
The HLA class II binding peptides libraries were compared to previously-determined numbers of BP and SB on all Class I HLA alleles for the same patients. On average, the number of alloreactive peptides bound to the two HLA-DRB1 alleles with an IC50<500nM, was far greater than the number 
Discussion
The data presented in this paper illustrate the large potential that HLA class I and especially HLA 35 . In realworld situations the term Py will have a time modifier, e t , associated with it, as protein expression and antigen amount declines over time because of tissue injury. This time relationship will be ignored for simplicity at this time. It is important to recognize that in HLA class I-presented antigen-driven T cell expansion, this term is utilized in its entirety given that HLA class I molecules are loaded using peptides derived from proteins present in the cytosol. This however is not the case for HLA class II molecules, which present antigens endocytosed from the extracellular environment 36 . This means that when calculating helper T cell growth, the term P will be modified to P.c, with a constant, c, reflecting the attenuation of antigen concentration given its 'scavenged' nature as opposed to direct cytosolic presence, in other words, 0 < c < 1 (for CD8+ T cells, c=1). Thus, the equation for determining helper T cell growth will take the general form,
Adjusting the variable P means that the absolute magnitude of the steady state T cell population for each of the dominant (high-ranked) helper T cell clones will be smaller than that for each of the dominant cytotoxic T cell clones, nevertheless because of the greater number of antigens presented by HLA class II molecules there will be a greater number of CD4+ T cell clones, and thus greater clonal diversity of helper T cells when compared to cytotoxic T cells. This also means that in a Power law clonal frequency distribution analysis 37, 38 , the contribution of the highest-ranking (most numerous) T cell clones to the entire repertoire will be higher with cytotoxic T cells. Conversely, in the T helper cell population there will be a larger number of high-ranking clones which contribute a larger component of the overall repertoire. Given the greater number of antigens there may be greater competition between the clones, which in a model accounting for competition between clones will lead to slower growth of helper T cell clones, a relatively frequent clinical observation 39 . Also, given the restriction of HLA class II molecules to antigen presenting cells the absolute magnitude of steady-state helper T cell clonal populations will be smaller; however, since HLA class I molecules are expressed on all nucleated cells, cytotoxic T cells get a proliferative signal from many different cell types, therefore steady state T cell clonal counts can be further augmented. From an evolutionary and T cell response sensitivity and specificity standpoint, it is logical that the cytotoxic T cell-recruiting signal provided by CD4+ T helper cells should be more sensitive, triggered by a greater variety of antigens, but when it comes to actual tissue destruction by CD8+
cytotoxic T cells, a more fine-tuned HLA class I bound, shorter peptide with greater specificity required for presentation, provides the necessary stimulus. This would come from the prevention of non-specific binding of peptide antigens to the more 'discriminating' HLA class I molecules.
Quantifying mHA-HLA-TCR interactions: On matrices, vectors & tensors
Following the above general discussion about T cell behavior, it is necessary to develop a model that will account for the potentially large arrays of antigens being presented in allogeneic SCT. As noted earlier, immunotherapy and SCT are fraught with the risk of treatment failure either in the form of relapsed malignancy or immune mediated normal tissue injury (GVHD or graft rejection). Various outcome prediction algorithms and models have been developed using increasingly sophisticated characteristics studied statistically 40, 41 . These may allow improvement in clinical outcomes prediction, but often do not provide mechanistic insight into the reason for the observed clinical outcomes. Further, while principles of immune therapy and the mechanisms of T cell action are well known from work on mouse models and in vitro 42, 43 , when the antigenic complexity encountered in vivo in human SCT recipients is considered, the existing models do not reliably predict individual clinical outcomes. This is also true of the T cell repertoire that emerges following SCT.
Nevertheless, mathematical methods are available that have long been used in physics to understand natural phenomenon and may be extrapolated to biological systems such as immune response modeling. For example, the concept of vectors and operators has been used to simulate aggregate T cell clonal responses to antigen arrays 22, 23 . However, this method is limited in that it requires identification of unique mHA-HLA and cognate TCR for application. To overcome this limitation, a related mathematical method, tensor analysis, may be used to simulate the immune responses to the vast library of tissue specific antigens presented by the entire spectrum of HLA molecules in an individual. In physics, tensors describe interaction between vector quantities and their components, so they enable determination of variation in vector magnitude and direction and subsequent mapping to a different 'state'. In other words, tensors help describe vector transformation when multiple forces are acting upon an object, which itself may be a vector 44, 45, 46 . It is important to recognize that these identifying interactions between specific molecules (e.g., p1 and p2). The identity matrix reflects the affinity of specific TCR for specific mHA-HLA combinations. It is to be noted that, the same peptides given above may bind other HLA molecules with a different affinity and there may be TCR which bind these alternative antigen complexes with different affinities, constituting different vectors ( Figure 5A & 5B). Along the same lines, a given peptide or TCR may interact with different partners yielding different vector components. For example, in the above matrices, TCR1 may interact with both H1p1 and H1p2, the magnitude of the former will be 1 and the latter, 0. However, given the continuous nature of the IC50s observed for different peptides with different HLA molecules in the analysis presented in this paper it is unlikely that the vector magnitudes are going to be binary in nature. The well-known phenomenon of immune cross reactivity is an example of the vector components which are not binary 48 .
It is also important to note that the forces (vectors) represented by B (H1p1) and Z (TCR1) may be considered orthogonal (perpendicular) because their direction is imparted by the unique recognition of peptide sequence by HLA, and that of peptide-HLA complex by TCR respectively. Thus, the growth of the T cell clone resulting from this interaction may be considered a 'cross' product of these two forces (Sin 90°=1, for orthogonal vectors) ( Figure 5C ).
T cell vector transformation: Enter Operators
In the SCT context the alloreactivity tensor, HpT, determines the magnitude (and direction) of T cell clonal growth vector in response to antigens. T cell clones with receptors TCR1 and TCR2 respectively will grow in response to the HpT Tensor. It is to be noted that the HLA-peptide driven T cell clonal growth vector is distinct from the TCR affinity vector for HLA-peptide complex, even if one considers that mHA-HLA affinity vector drives T cell clonal growth of the relevant TCR bearing clone. This relationship is analogous to applied force, resulting in motion at a certain velocity and consequent mass displacement which are distinct vector quantities pointing in the same direction (with time being the scalar distinguishing between them; T cell clonal growth is also a time-dependent function). In the above example, the T cell clonal growth vectors, comprising the two T cell clones bearing the T cell receptors TCR1 and TCR2, are termed T1 and T2 respectively. These constitute a vector matrix, which is Additionally, the checkpoint mechanism (CP) comprising the PD1 receptors, if engaged may be represented by a variable valued at 0 because no T cell growth will occur, and when absent, valued at 1. Figure 2) 49, 50, 51 . Considering that all these variables contribute to T cell growth, the term r is therefore a composite of the following factors,
Finally, 'Signal 3', (S3) represents the effect of cytokines on T cell growth (Supplementary
Solving this equation for lack of PD1 engagement (1) and the presence of CD28 expression (1) yields,
Solving the equation for CTLA4 expression or PD1 engagement gives r a value of 0, which yields e 0 = 1 in equations 1 & 2, consistent with suppression of T cell growth. In other words, the presence of PD1 engagement by PDL-1 or the engagement of CTLA-4 instead of CD28, by CD80 on APC, changes r to zero, eliminating the effect of time t, which changes the value of e to 1 (in equation 2), leading to growth arrest of the T cell clone.
As for S3, the cytokine mediated signal may also be considered a second order tensor quantity, Further complicating these estimations from a physical standpoint at a cellular level in equation 8 , cytokine exposure will be variable since these effects are 'local' to the tissue or lymph nodes.
Cytokines likely depend on diffusion via capillary action in the extracellular matrix to create a 'field' in which the T cells experience the cytokine effects. These effects on growth are of an exponential nature because of r being an exponent in equations 1 & 2 52 . The receptor expression levels also vary on different cells and confer a direction by means of influencing differentiation and functional specificity to the T cell clones with unique TCR.
Evolution of the T cell repertoire: Putting it all together
The above discussion illustrates the complexity inherent in the multiple factors influencing the T cell responses to antigens presented by HLA molecules. Nevertheless, it makes it clear that despite the complexity, it is possible to describe the immune interactions in mathematical terms, and therefore it is also possible to simulate them, especially when antigen presentation data are available. To do so one may take the example of a random collection of tissue associated peptides. First, consider an alloreactive peptide of any size varying between 7-18 amino acids. This peptide will have a choice of binding to HLA class I and II molecules (there are six of each). Therefore, depending on its size and mode of acquisition (extracellular or cytosolic) it will bind to the relevant HLA molecules with a unique binding affinity. It is to be noted that depending on the number of binding HLA molecules and the concentration of competing peptides, there will be a probability function associated with each of these interactions. As demonstrated above in equations 4 and 5, the mHA (polymorphic peptide) binding affinity to available HLA molecules, may be considered to represent the components of the immune response vector to this antigen (or degrees of freedom for the peptide). For most peptides, only one component (one HLA-mHA complex) with the strong interaction will be relevant, and others with weak interactions may be ignored.
With the peptide bound to one of the HLA molecules (or more depending on binding affinity with other HLA molecules), it is presented on the APC. If a T cell clone with a TCR which has affinity for the HLApeptide complex is present (a second probability term), then depending on the CD28/CTLA-4 and PD1 expression levels in the T cell clone, it will grow in the cytokine 'field' present in the tissue.
Thus, consider peptides (p1, p2 ... pn) with high affinities B1, B2… Bn for HLA molecules H1, H2… Hn respectively, but with a very low-level affinity for the non-corresponding HLA molecules present in the individual (e.g., the components p1H2, p2Hn, pnH1, not considered here for the sake of simplicity in illustration, but fundamental to the tensor concept). These mHA-HLA complexes have corresponding T cell receptors TCR1, TCR2… TCRm with affinities, Z1, Z2… Zm, the tensor HpT may be written as follows, The aggregate alloreactive T cell response at time, t is then
This general equation describes the transforming effect of the alloreactivity tensor and the cytokine tensor on the T cell repertoire following SCT. The risk of alloreactivity developing clinically will in this instance be proportional to Nt(TM).
Dynamical system model of alloreactive T cell response and clinical observations
Does this model explain observations in clinical transplantation? To determine this one may consider the matter of HLA-DPB1 mismatching and alloreactivity in 10/10 HLA matched DRP 53, 54 , and for that matter the general problem of HLA mismatched SCT and associated negative clinical outcomes 55 . In the dynamical system model this phenomenon may be easily understood; the mismatched HLA DPB1 epitopes are highly expressed so instead of having a fraction of the protein expressed (the term P.c in Eq. 2) governing CD4+T cell clonal growth, T cell clones bearing TCR that recognize epitopes on HLA DPB1 encounter an order of magnitude higher target concentration with a marked amplification of the steady state alloreactive T cell clonal populations compared to a standard HLA class II bound mHA. Indeed, polymorphisms impacting the level of HLA DPB1 expression correlate with the likelihood of GVHD developing 56 . Further any peptides bound to the mismatched HLA will be novel antigen complexes for the donor T cell clones to recognize. This would result in a strong aggregate immune response to the mismatched HLA (and its presented peptides) which is widely expressed, and this response is significantly larger than a mHA-HLA directed immune response.
Despite the ability of the model to explain some common clinical observations (logistic growth of T cells, power law distributions, and CD4/CD clonal distribution), it will not be validated unless it explains the random occurrence of GVHD following allografting. A discussion of this has previously been presented, where the competition between non-alloreactive and alloreactive peptides for HLA binding and presentation was invoked as a possible reason for this, resulting in a probability distribution ( Hpn) for the alloreactive peptide pn to be presented on HLA molecule H. A further consideration in the development of GVHD from these alloreactive T cell clonal growth simulations is the probability function introduced by peptide cleavage potential, which affects the likelihood of antigen presentation, as well as whether the relevant T cell clones are present following transplantation ( Tm). The probability of peptide cleavage ( cl) is determined by the amino-acid sequence at the C terminal of the peptide antigens 57 , as such, several peptides in our study may have low likelihood of presentation and may be ignored to simplify the model. The likelihood of alloreactive antigen response ( yz{| ) may then be calculated as yz{| = 2 }~• * {} € 7 * % v …. [11] Computed for each alloreactive peptide, the probability of clonal expansion of the mHAtargeting-T cells will be significantly diminished as the number of probability terms are introduced into the computations, which explains why despite many potential alloreactive antigens being present in each donor and recipient not every patient develops GVHD.
Another clinical phenomenon, the T cell growth amplification effect of cytokines is well recognized clinically. This is recognized in both the need for lymphodepletion prior to adaptive immunotherapy and in the cytokine release syndrome seen following it 58, 59 . Thus far in the dynamical system model discussed above the cytokine tensor effect has been described as modulating rate of T cell clonal growth. However, cytokines effect not only the rate, but they also effect the magnitude of clonal expansion, amplifying the T cell clonal growth. This may be modelled using the iterating equation A final consideration in building this model is that the antigen matrices presented above are 'identity matrices' with binary values of, 1 along the diagonal of a square matrix and 0 elsewhere. In physiologic conditions, however there will be a continuum of values because of differential binding of peptides to various HLA molecules and cross reactivity of T cell receptors with such antigen complexes, generating random number matrices, rather than identity matrices 60 . This will add another element of complexity to the antigen-effector interactions, and possibly provides a rationale for complex GVHD phenotypes observed.
In conclusion, there is considerable genetic variation present between HLA matched transplant donors and recipients. In silico, this yields a putative large array of recipient mHA bound to both HLA class I and class II molecules, which when viewed from the frame of reference of responding donor T Figure 1) . A.
GENEIDS
B.
C. Overlapping Sequence -overlapping amino acid sequences (3 or greater consecutively) in both 9-mer and 15-mer peptides which bind their respective HLA classes (n=268); 3) Multiple mixture: At least 1 sequence identical or nested match and at least 1 gene-matched set of discrete peptides nearby (exhibiting no sequence identity, only matched at the gene-expression level, Gene X above) (n=102); 4) gene-matched set of discrete peptides nearby to one another in proximity (exhibiting no sequence identity, only matched at the gene-expression level, Gene Y above) (n=143).
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Control of T cell growth rate by the immunological synapse and Signals S1
(TCR-ab), S2 (CD28/CTLA-4) and S3 (IL-12R), along with checkpoint molecules (CP) PD1. 
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